|
Volumn 94, Issue 16, 2002, Pages 1184-1185
|
The need for and characteristics of randomized, phase III trials to evaluate symptom management in patients with cancer
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTINEOPLASTIC AGENT;
NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;
CANCER GROWTH;
CANCER PAIN;
CANCER PATIENT;
CANCER RESEARCH;
CANCER SURVIVAL;
CANCER THERAPY;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DATA ANALYSIS;
DEPRESSION;
DISEASE COURSE;
DISEASE SEVERITY;
DRUG RESPONSE;
EDITORIAL;
FATIGUE;
GOOD CLINICAL PRACTICE;
HUMAN;
LUNG CANCER;
MEDICAL ASSESSMENT;
MEDICAL LITERATURE;
METHODOLOGY;
PHASE 3 CLINICAL TRIAL;
POPULATION SIZE;
PRIORITY JOURNAL;
PSYCHOMETRY;
QUALITY OF LIFE;
RANDOMIZED CONTROLLED TRIAL;
REPRODUCIBILITY;
SCORING SYSTEM;
SELF REPORT;
SENSITIVITY ANALYSIS;
STANDARDIZATION;
SYMPTOM;
TREATMENT OUTCOME;
|
EID: 0037151386
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/94.16.1184 Document Type: Editorial |
Times cited : (26)
|
References (8)
|